GSK (LON:GSK – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Deutsche Bank Aktiengesellschaft in a note issued to investors on Wednesday, Digital Look reports. They currently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential upside of 6.87% from the company’s current price.
Several other equities analysts have also weighed in on GSK. Citigroup cut their target price on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a report on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, GSK has an average rating of “Hold” and a consensus price target of GBX 2,048.57.
GSK Price Performance
GSK (LON:GSK – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Sell-side analysts forecast that GSK will post 175.980975 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, insider Jonathan Symonds bought 1,550 shares of the company’s stock in a transaction that occurred on Friday, June 19th. The shares were purchased at an average price of GBX 1,935 per share, for a total transaction of £29,992.50. Also, insider Jeannie Lee bought 802 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of GBX 5,069 per share, with a total value of £40,653.38. In the last three months, insiders bought 3,618 shares of company stock valued at $13,481,942. Company insiders own 0.20% of the company’s stock.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Featured Stories
- Five stocks we like better than GSK
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
